Demographics of Study Cohort (n = 21,167)
| Demographic | Data |
| Age (y) | 74 (70–80) |
| Signs or symptoms prompting scan | |
| A single other sign | 639 (3.0) |
| Elevated or rising PSA level only | 6,355 (30.0) |
| Evidence from other imaging | 1,532 (7.2) |
| Pain only | 4,826 (22.8) |
| Multiple signs | 2,279 (10.8) |
| None | 5,536 (26.2) |
| Summary stage | |
| Local/NED | 7,922 (37.4) |
| LN+/regional | 1,563 (7.4) |
| Single metastasis | 1,994 (9.4) |
| Multiple metastases | 6,263 (29.6) |
| Unknown | 3,425 (16.2) |
| Results of NaF PET scan | |
| Benign or equivocal | 11,880 (56.1) |
| Probable | 1,869 (8.8) |
| Definite | 7,418 (35.0) |
| Diffuse | 2,052 |
| Multifocal | 4,675 |
| Unifocal | 691 |
| Comparison of physicians’ estimates of extent of disease before and after PET | |
| Less extensive after PET | 5,254 (29.1) |
| More extensive after PET | 6,497 (35.9) |
| No change | 6,329 (35.0) |
PSA = prostate-specific antigen; NED = no evidence of disease; LN+ = lymph nodal disease positive.
Data are n followed by percentage in parentheses, except for age, which is median followed by interquartile range.